Oncology Data Advisor: Recent Episodes
i3 Health
The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.
Read the full article at: https://oncdata.com/real-world-evidence-ai-in-oncology Artificial intelligence (AI) is rapidly transforming oncology research, but its impact depends on high-quality data. As researchers increasingly rely on real-world evidence (RWE) to complement clinical trials, ensuring that data is accurate, complete, and transparent has become just as important as developing new AI tools. In this episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Saamir Pasha, Senior Biostatistician at Ontada, about two complementary areas of innovation—the establishment of rigorous frameworks to assess the quality of oncology real-world data, and the exploration into how generative AI can accelerate complex biostatistical workflows while maintaining scientific rigor and regulatory transparency. Together, these efforts illustrate how AI is poised to enhance—not replace—the expertise required to generate reliable evidence in oncology.
Read the full article at: https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.
Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains inconsistent. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights the critical shift that is moving AI from theoretical promise to practical application.
Are you treating extrapulmonary neuroendocrine carcinomas based on where they start—or what they actually are?In this faculty follow-up to their i3 Health activity (Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets), Andrew Hendifar, MD, and Danielle Hutchings, MD (Cedars-Sinai Medical Center), unpack why treating these rare, aggressive tumors according to site of origin rather than tumor lineage can compromise outcomes. They clarify crucial pathologic distinctions between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) while emphasizing the essential role of multidisciplinary collaboration in precision care.The experts also explore the novel therapeutic landscape of delta-like ligand 3 (DLL3)–targeted therapies, highlighting the promise of DLL3 T-cell engagers in extrapulmonary disease. They address ongoing diagnostic hurdles—such as standardized immunohistochemistry (IHC) expression thresholds and expanding send-out testing access—while sharing key insights on emerging clinical trials evaluating T-cell engager monotherapies and chemo-immunotherapy combinations.Claim your CME credit: bit.ly/488fPhKDownload and review the companion Clinical Challenges in Extrapulmonary NEC Slide Deck: bit.ly/4w2Pni3
What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies?In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO that is actively reshaping care algorithms across the prostate cancer continuum. Dr. Freedland dives into the breakthrough TALAPRO-3 trial—exploring why talazoparib plus enzalutamide is making waves across diverse HRR alterations (including BRCA and ATM)—and analyzes how the PROTEUS trial’s 35% reduction in subsequent salvage therapies could redefine surgical planning for high-risk localized disease. Plus, get an insider's look at what’s on the horizon with PSMA PET imaging, T-cell engagers, and AR degraders.🎓Complete the Educational Activity: https://bit.ly/4x2BnWf
Chronic inflammatory demyelinating polyneuropathy (CIDP) presents significant challenges in both diagnosis and long-term disease management. As consensus definitions, emerging targeted therapies, and research into serologic biomarkers evolve, how can clinicians optimize individual care algorithms?In this follow-up discussion, Karissa Gable, MD, Duke University Medical Center, breaks down recent breakthroughs in CIDP care and trial design:- Standardizing CIDP Terminology: Key updates from the new international consensus definitions paper establishing unified criteria for disease remission, stability, treatment response, and refractory disease.- The Emerging Pipeline: What’s next in therapeutic development, including FcRn antagonists (nipocalimab and batoclimab) and complement inhibitors.- Shared Decision-Making: Practical strategies for tailoring therapy selection based on patient preferences, lifestyle, comorbidities, and administration routes.- Building Confidence in CIDP Care: Applying 2021 EAN/PNS guidelines to navigate diagnosis and ongoing treatment adjustments when first-line options fall short.💡 Complete the Educational Activity: https://bit.ly/4pPcVWe👉 Access the accompanying slide deck for comprehensive guidance on CIDP detection and management: https://bit.ly/4pPcVWe
Read the full article here: https://oncdata.com/information-overload-and-the-portal-patient The way that patients receive medical information has changed dramatically. Through electronic health record portals, laboratory values, imaging reports, and pathology results often become available the moment they are finalized—sometimes before a physician has had the opportunity to review or discuss them. While this unprecedented access promotes transparency and patient engagement, it also creates new challenges for communication, trust, and anxiety management. In the latest episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, to explore how instant access to test results is reshaping oncology care.
Read the full article here! https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.
Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient?In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on:🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles.🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy.🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients.📅 Save Your Spot for the Live Event!Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman.Session 1: July 8 at 6:00 pm ET: bit.ly/3SitVaCSession 2: July 28 at 7:00 pm ET: bit.ly/4oIAcZo
View the full article at: https://oncdata.com/oncology-unfiltered-tumor-board-vs-tuesday-afternoon Tumor boards play a pivotal role in oncology care. For clinicians, they represent the ideal environment: multiple specialists, shared context, and time to debate the gray areas that guidelines can’t fully capture. However, during a busy afternoon in the clinic, the plans developed in tumor boards often prove less straightforward to implement. In this episode of Oncology Unfiltered, Melissa Cutrona, MS, and Matthew Hadfield, DO, OncData Editor in Chief, unpack why tumor boards are so valuable, where they fall short, and how to bridge the gap between a coordinated plan and the reality of care delivery on a busy clinic day.
Check out the full article at: https://oncdata.com/oncology-unfiltered-the-real-world-vs-the-trial-patient Every oncologist knows the moment well: you're reviewing treatment options with a patient, guidelines in hand, when you realize the person sitting across from you wouldn't have qualified for the pivotal trial that established your recommended therapy. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, speaks with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, about one of oncology's most persistent challenges—the widening gap between carefully curated trial populations and the complex, real-world patients who enter clinics daily.
Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains uneven. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights a critical shift: moving AI from theoretical promise to practical application.
or mild compared to the severe jaundice seen in infants.Diagnostic Red Flags: When to move beyond standard autoimmune panels and look for genetic markers.Genetic Testing 101: A comparison of targeted gene panels vs. whole exome sequencing for the most efficient diagnosis.The Power of a Name: How a specific PFIC diagnosis changes everything—from family counseling to starting life-altering IBAT inhibitors.💡 Earn 1.5 Free CME/AAPA Credits👉 Join the Escape Room: i3health.com/pfic
Read the full article at: https://oncdata.com/exploring-ai-helioliverPatients diagnosed with early-stage liver cancer have a significantly higher survival rate compared to those diagnosed in later stages, yet screening options and barriers persist. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Bharat Tewarie, MD, MBA, the CEO of Helio Genomics, about the company’s AI-powered blood test, HelioLiver, and its potential role in detecting hepatocellular carcinoma (HCC), the most common form of liver cancer. Dr. Tewarie shares why liver cancer is a strong use case for blood-based early detection, how HelioLiver may fit into existing workflows, and barriers to overcome for broader adoption.
is the new benchmark in localized disease and how to integrate these advances into your clinical practice today.Interested in the complete CE activity?Complete Module 1: https://bit.ly/45u106oComplete Module 2: https://bit.ly/3HtOziO
Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.
Choosing Not to Treat: How Do You Know When the Best Treatment Is No Treatment? by i3 Health
Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Don't forget to take the activity and claim your credit after the episode!Click here to take module 1 of the activity: bit.ly/3Y3ivHM
perspective clinicians need to stay ahead. Listen now to discover what the future holds for hemophilia management!Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj
Read the full article at: https://oncdata.com/inav-daniel-kingPancreatic cancer remains one of oncology’s most challenging diseases—fast-moving, hard to detect early, and often diagnosed after curative options have narrowed. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, speaks with Dr. Daniel King, Gastrointestinal Medical Oncologist at Northwell Health and co-inventor of iNav, an AI-enabled navigation platform designed to expedite diagnosis and treatment for patients with suspected pancreatic cancer.
Neuroendocrine tumor (NET) care is changing fast—and the pace of innovation is only accelerating. In this episode, Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), breaks down the latest advances that are reshaping how clinicians diagnose and treat NETs.Dr. Chauhan, who recently chaired i3 Health’s CME activity Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, returns to highlight what’s new and what matters most for practice. From evolving epidemiologic insights to emerging targeted therapies and next‑generation immunotherapies, he explains how these developments are expanding options for patients and refining real‑world decision making.Whether you’re a clinician treating NETs, a trainee looking to stay current, or a listener interested in where cancer care is headed next, this conversation offers a concise, high‑yield tour of the NET landscape—and where it’s going next.Click the link to view the full activity and claim your free CME credit: https://bit.ly/41Qo65YClick here to download/view the infographic: https://bit.ly/4bbSUmL
that can overwhelm even the most seasoned clinicians. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, to discuss whether we are over-testing, under-testing, or simply testing the wrong things at the wrong time.Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”
Read the full article on Oncology Data Advisor:https://oncdata.com/oncology-unfiltered-financial-toxicityIn this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, explore how financial and geographic toxicities in oncology are, in reality, clinical toxicities. If a patient can’t afford to fill the prescription, is it really a treatment option?They discuss what financial toxicity truly means—far beyond drug prices—covering travel, parking, time off work, and the hidden costs of tests and therapies. Dr. Hadfield shares real-world examples of patients turning down innovative treatments and clinical trials because they can’t afford the logistical burden, and explains how geography and income create a two-tiered system of cancer care.The conversation examines how financial and geographic barriers distort shared decision making, limit participation in clinical trials, and skew our understanding of real-world efficacy. They also highlight the role of institutions, policymakers, and pharma in improving access, and why oncologists must reconsider ordering patterns, testing habits, and how they counsel patients about the full “cost” of care.Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”
Psoriatic arthritis management is evolving fast, but bridging the gap between clinical evidence and patient experience remains the ultimate challenge. When multidisciplinary teams and patients truly sync, care transforms.i3 Health recently convened a Multidisciplinary Task Force to discuss early screening, comorbidities, and therapeutic optimization. In this exclusive follow-up interview, we sit down with Archie Franklin, MBA—a veteran PsA patient and Task Force moderator—to go beyond the data. Listen now to hear a unique, dual-perspective look at the changing treatment landscape, sharing candid reflections on how clinicians can bridge communication gaps and practically elevate outcomes for every patient.Click the link to view the Task Force and claim your free CME/NCPD/CPE credit: https://bit.ly/4h5NSKb
With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity.Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB
With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 1 of the full podcast activity.Click the link to complete module 1 and claim your free credit: bit.ly/4iYmYD2
Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available.You can catch the live session on either of these dates:Wednesday, January 8 at 5:00 pm ET: https://bit.ly/4iZxnA0Monday, January 26 at 5:00 pm ET: https://bit.ly/4qALw9J
Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!Tuesday, January 13 at 5:00 pm ET - bit.ly/4p7HRilMonday, February 2 at 7:00 pm ET - bit.ly/495gnEd
Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.
Don't forget to claim your credit after the episode!Click on the link to claim your credit for module 2: bit.ly/43VoFNP
Don't forget to claim your credit after the episode!Click on the link to claim your credit for module 1: bit.ly/3Y3ivHMClick here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP
Read the full article at: https://oncdata.com/travis-osterman-ai-informatics In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Dr. Travis Osterman, Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center, about the evolving role of health informatics in oncology. Their conversation spans training pathways, precision oncology, data standards, AI integrations, and the strategies to promote adoption in both academic and community practices.
Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies.🎧 Listen now and click the link to claim your CE credit!Claim your credit here: bit.ly/4pGrLO5🔗 Learn more and access continuing education activities: i3health.com📲 Stay connected with i3 Health:Twitter/X: https://bit.ly/3ITDaJVFacebook: https://bit.ly/46wmwJoYouTube: https://bit.ly/46PXLXx🎧 Subscribe to the Oncology Data Advisor Podcast on your favorite streaming platform so you never miss the latest expert discussions!
Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!Click the link to claim your CE credit:
Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool.
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!Click here to claim credit for this activity: https://bit.ly/3HtOziOClick here to listen to Module 1 of this series: https://bit.ly/45u106o
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!Click here to claim you CE credit for this activity: https://bit.ly/45u106oClick here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO
Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians.Click here to complete the free CME/NCPD/CE activity: bit.ly/3HqXjpX
i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC).In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!Click below to complete the claim your CE credit:Module 2: https://bit.ly/405xEJOClick below to complete the Module 1 from this series, HER2 in NSCLC: Actionable Insights and Testing RecommendationsModule 1: https://bit.ly/49NCaQu
i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!Click below to complete the claim your CE credit:Module 1: https://bit.ly/49NCaQuClick below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLCModule 2: https://bit.ly/405xEJO
oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM.In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration.Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!Register Here: bit.ly/3UgV7nF
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education. Click the links below for the full CME activity!Module 1: https://bit.ly/3X8apxaModule 2 : https://bit.ly/41rS14IModule 3: https://bit.ly/4b9JU00And view the slide decks here:Module 1: https://bit.ly/4l0NTzcModule 2: https://bit.ly/4fdXwtiModule 3: https://bit.ly/40AkmoP
As research in dedifferentiated liposarcoma (DDLPS) continues to advance, the importance of multidisciplinary collaboration and access to innovative therapies remains at the forefront of patient care. Recently, Dr. Richard Riedel of Duke Cancer Institute and Dr. Candace Haddox of Dana-Farber Cancer Institute co-chaired i3 Health’s DDLPS Task Force activity, which brought together a panel of experts to address the complexities of this rare and challenging sarcoma subtype. With new clinical trials underway and a growing understanding of the disease’s molecular landscape, Dr. Riedel and Dr. Haddox sat down to highlight promising research directions and insights in honor of Sarcoma Awareness Month in July.After listening to the interview, stay tuned to hear the full accredited podcast with Dr. Riedel and Dr. Haddox, and click the link below to claim free CME/AAPA credit.Click the links below for the Task Force activity!- Accredited CME/AAPA Podcast: i3health.com/course-information/podcast-ddlps- Position Statement Published in Cancer Treatment Reviews: www.cancertreatmentreviews.com/article/S…/fulltext- Live Task Force Recording: youtu.be/Otr5_tiFQ68
Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs.In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration.Don’t miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!Register Here! July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registrationAugust 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration
A Return on Humanity: How the American Cancer Society Uses AI to Improve Patient Care by i3 Health
Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape.Click here to claim your credit for this podcast:
Read the full article for this interview here: https://oncdata.com/standard-model-biomedicine Artificial intelligence (AI) is rapidly transforming the landscape of oncology, offering new tools to improve patient care and accelerate research. In this episode of Exploring AI in Oncology, Dr. Waqas Haque sat down with Kevin Brown, Founder and CEO of Standard Model Biomedicine, to discuss the challenges and opportunities of implementing AI in cancer care.
Read the full article here: https://oncdata.com/reimagining-oncology-nursing-through-ai In this episode of the Exploring AI in Oncology series, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Kathleen McGrow, Sangeeta Agarawal, and Marc Perkins-Carrillo about their presentation at the Oncology Nursing Society (ONS) Congress about the intersection of artificial intelligence (AI) and oncology nursing. Their conversation highlights the transformative potential of AI in nursing, the skills needed to navigate this evolving landscape, and the ethical considerations that must guide its implementation.
In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments.Click here to go back and listen to module 1 of this podcast series: https://bit.ly/4iYmYD2Click here to claim your CME/NCPD credit: https://bit.ly/44yO9RB
Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually.Click here to listen to module 2 of this podcast series: bit.ly/44yO9RBClick here to claim your CME/NCPD credit: bit.ly/4iYmYD2
In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai’s innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.
Tune in to Module 2 of our podcast series as Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, explores strategies for developing personalized management plans for patients with systemic mastocytosis (SM). This episode covers the latest advancements in treatment, including tyrosine kinase inhibitors (TKIs), supportive care interventions, and practical approaches to tailoring therapies based on disease subtype and symptom burden. Listen now to stay up to date on best practices for improving patient outcomes and quality of life—and don’t forget to claim your credit after the episode!Click here to claim credit for this activity: https://bit.ly/43VoFNP
Join Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, in Module 1 of this podcast series as she explores the challenges of diagnosing systemic mastocytosis (SM), a rare and often under recognized mast cell disease. In this episode, Dr. Castells discusses the wide range of SM symptoms—including anaphylaxis, cutaneous, gastrointestinal, neuropsychiatric, and musculoskeletal manifestations—and offers essential guidance on recognizing the signs, confirming the diagnosis, and improving patient outcomes through early intervention. Listen now to enhance your clinical knowledge and be sure to claim your credit after the episode!Click on the link to claim your credit now: https://bit.ly/3Y3ivHMClick here to continue listening to Module 2 of this podcast series: https://bit.ly/43VoFNP
The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical.In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease.Don’t miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice.Click below to access these valuable resources:Accredited CME/NCPD Podcast: bit.ly/3B4gSB1Position Statement in Blood Cancer Journal: www.nature.com/articles/s41408-024-01129-0Live Task Force Recording: www.youtube.com/live/TILCPB6w3Ig?…=1Z8m4dA2qwLJd6rN
March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month. Click the link for the full activity! https://bit.ly/4hyVwLn
As we recognize Kidney Cancer Awareness Month this March, advancements in renal cell carcinoma (RCC) treatment continue to evolve. Recently, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, a Nurse Practitioner and expert in genitourinary oncology, chaired the i3 Health’s NCPD activity titled Toxicity Management and Symptom Control in Advanced RCC: Playbook Update. In this interview, she shares updates in RCC treatment, strategies for toxicity management, and the importance of patient education.Click here for the full NCPD activity! https://i3health.com/course-information/toxicity-management-and-symptom-control-in-advanced-rcc-playbook-update
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 3 of the activity, including questions he commonly gets from patients about MCED testing and advice for clinicians about employing shared decision making with patients to choose the most appropriate type of cancer screening for them. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. Click here to claim your CME credit: https://bit.ly/4b9JU00
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 2 of the activity, including the value of MCED testing for cancer survivors and ongoing trials investigating MCEDs that he’s looking forward to seeing results of in the near future. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. Click here to claim your CME credit: https://bit.ly/41rS14I
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 1 of the activity, including how MCED testing is helping to address the cancer screening gap in the US and the importance of staying up to date on developments in MCED testing. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. Click here to claim your CME credit: https://bit.ly/3X8apxa
In this episode of the Exploring Artificial Intelligence (AI) in Oncology series, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Osama Khan, MD, Staff Pathologist at Natera, a cell-free DNA (cfDNA) technology company that aims to make personalized genetic testing and diagnostics part of the standard of care. Dr. Khan shares insights into how digital pathology and emerging technologies like AI and measurable residual disease (MRD) testing are revolutionizing oncology, driving precision medicine, and enhancing patient care.Learn more at: https://oncdata.com/digital-pathology-osama-khan
Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology-Oncology, and Professor of Pediatrics at Keck School of Medicine at the University of Southern California (USC), is currently serving as co-chair of i3 Health’s CME/NCPD activity, Practice-Changing Advances in the Management of Hemophilia. With new developments in the field occurring over recent months, Dr. Young sat down with us to share recent updates in the hemophilia treatment and management. Click the links below for the full activity!Online accredited CME/NCPD activity: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophiliaAccredited CME/NCPD podcast: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia-podcast
The role of artificial intelligence (AI) and machine learning (ML) in precision oncology has expanded rapidly, offering promising tools for clinicians and researchers to deliver more targeted and efficient care. During the 2024 San Antonio Breast Cancer Symposium (SABCS), Fellows Forum member Dr. Jasmin Hundal conducted an interview with Ian Maurer, Chief Technology Officer at GenomOncology, to explore the applications, challenges, and future directions of AI in oncology. Learn more at: https://oncfellows.com/how-ai-is-revolutionizing-precision-oncology
Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel’s innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney
Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!Click here to claim CME/NCPD credit: https://bit.ly/405xEJO
Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!Click here to claim CME/NCPD credit: https://bit.ly/49NCaQu
In this episode of Exploring Artificial Intelligence in Oncology, Wanmei Ou, PhD, the Vice President of Product, Clinical Decision Support, & Analytics Data Platform at Ontada, shares more about Ontada’s collaboration with Microsoft to transform unstructured oncology data with Azure OpenAI technology. Her discussion with Dr. Waqas Haque highlights how AI is transforming clinical workflows, reducing documentation burdens, and driving improved patient outcomes.Learn more at: https://oncdata.com/ontada-microsoft-azure-ai-real-world-data-processing-in-oncology/
The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to provide oncology clinicians with insights into its significance and implications for clinical practice.Learn more at: https://oncdata.com/zanidatamab-biliary-tract-cancer-james-harding/
As Lung Cancer Awareness Month progresses, this discussion hosted by Oncology Data Advisor sheds light on the advancements in lung cancer therapies, unmet needs, the evolving landscape of molecular testing, and actionable insights for clinicians.
Gain valuable insights into the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) and earn free CME credit with our latest podcast. This episode features expert guidance from Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. Delve into the latest on identifying MDM2 and CDK4 amplification, challenges in diagnosing DDLPS, and updates on emerging therapies like CDK4/6 inhibitors and immunotherapies. Learn how a multidisciplinary approach enhances patient outcomes in this rare and aggressive soft tissue sarcoma. Listen now and advance your expertise!Click here to claim your CME credit: i3health.com/course-information/podcast-ddlps
The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?
Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO by i3 Health
i3 Health is pleased to invite you to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, a free, live webinar held on November 7 at 10:00 am Eastern and November 19 at 11:30 am Eastern. This interview features an exclusive preview from the two webinar co-chairs, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center. Click below to register for this insightful webinar and enhance your understanding of genetic testing and counseling in cancer care!Register for the webinar: https://i3health.com/course-information/pathways-to-precision-integrating-genetic-counseling-and-testing-into-cancer-care
In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque, MD, sits down with Aamir Ehsan, MD, the Founder and CEO of CorePath Laboratories in San Antonio, Texas. Together they discuss how CorePath utilizes AI in pathology.
Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health’s accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With new developments in the field occurring over recent months, Dr. Wong sat down with us again to share new updates in treatment and management of HNSCC.Click here for the full activity: https://i3health.com/course-information/hnscc-harnessing-immunotherapy-in-comprehensive-care
Jeff Sperry, PharmD, BCPS, a Clinical Pharmacist at UCHealth Memorial Hospital, discusses additional advances in chronic kidney disease since recording the i3Health CPE-accredited activity, Slowing Progression of Chronic Kidney Disease Through Value-Based Care. Following the interview, continue listening for the complete CPE-accredited podcast.Click this link to claim your free CPE certificate: https://i3health.com/course-information/chronic-kidney-disease
Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma.To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm
Click here to view the full activity and claim free NCPD credit! https://i3health.com/course-information/managing-immune-related-adverse-events-to-ensure-optimal-cancer-immunotherapy-outcomes-the-nurses-viewAt last year’s Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit, i3 Health hosted a nursing continuing professional development (NCPD) symposium entitled Managing Immune-Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes (IRAEs): The Nurse’s View, chaired by Blanca Ledezma, MSN, NP, AOCNP®, Hematology/Oncology Nurse Practitioner at UCLA Health. With numerous advances in the immunotherapy space occurring since the symposium was held, Oncology Data Advisor Editorial Board member Beth Sandy, MSN, CRNP, Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, sat down to discuss some of these updates in lung cancer and her own insights on optimal management of IRAEs from the nursing perspective.
In this episode of Exploring Artificial Intelligence (AI) in Oncology, Dr. Waqas Haque sits down with Dana Brown, the President, CEO, and Chairman of the Board at iCAD, a company whose mission is to use innovative AI solutions that empower providers to accurately, reliably, and quickly detect cancer and improve outcomes. Ms. Brown shares more about iCAD’s products and recommendations for how to integrate AI into the clinic, including: •Her own background in the technology industry and why she joined iCAD•The products and solutions that iCAD offers•How iCAD utilizes AI to improve mammography accuracy•The ProFound Breast Health Suite and how it enhances cancer detection and patient outcomes•Their recent partnership with Densitas and CancerIQ and their impact on breast health•What distinguishes iCAD’s AI algorithms from other solutions in the market•The importance of company culture in driving success of AI startups and defining traits behind iCAD’s success•Recommendations for clinicians in practice to learn about and integrate AI into their workflow•And more!
Claim free CME credit at: https://i3health.com/course-information/mced-3Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application.In Module 3 of our CME podcast, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, will explore the practical implementation of multicancer early detection (MCED) tests into clinical practice, offering valuable insights into how these innovations could transform cancer screening and improve patient outcomes.
Claim free CME credit at https://i3health.com/course-information/MCED-2Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application.Join Dr. Charles Vega in Module 2 of our CME podcast as he delves into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, the role of early detection has never been more critical. Dr. Vega will unpack the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, exploring their potential to revolutionize cancer screening and improve patient outcomes.
Claim free CME credit at https://i3health.com/course-information/mced-1 Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application.Listen to Module 1 and join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge realm of multicancer early detection (MCED). Dr. Vega will delve into the scientific foundations of blood-based cancer screening, highlighting both current limitations and the promising potential of MCED technologies. Learn how these revolutionary tests harness biomarkers to detect multiple cancers in a single, convenient screening—a game-changer in overcoming barriers like low awareness and limited access to screening facilities.
In this Fellows Forum podcast episode, Dr. Richa Thakur, Palliative Care Physician and Hematology/Oncology Fellow at Northwell Health, speaks with Dr. Janet Abrahm, one of the founders of the field of palliative care in the United States. Dr. Abrahm shares insights into her career and research in palliative care, including: •How palliative care in oncology isn’t just for end of life—it’s for enhancing patient outcomes•How palliative care serves as a partner for the oncology team •The value of palliative care training for hematology/oncology fellows•How to cope with the moral distress and compassion fatigue that clinicians may experience when treatment doesn’t work for their patients •The stages of grief (denial, anger, bargaining, depression, acceptance) and how they can be experienced by both patients and clinicians•The importance for both oncology and palliative care fellows to find an outlet for their grief •Dr. Abrahm’s website and book, “Comprehensive Guide to Supportive and Palliative Care for Patients with Cancer,” which feature a wealth of information for busy practicing oncology and palliative care clinicians•And more!
In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Luis Valente, CEO and Co-Founder of iLoF, a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development.
In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Dr. Tamir Wolf, Co-Founder and CEO of Theator, a company pioneering next-generation AI and computer vision technology to automatically capture and analyze surgical data in real time to generate actionable insights and improve surgical outcomes.
In this podcast, hear expert perspectives on practice-changing advances in the treatment and personalized management of patients with hemophilia from Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology/Oncology, and Professor of Pediatrics at Keck School of Medicine of USC; and Dr. Jennifer Davila, Co-Director of the Hemophilia Treatment Center at Montefiore and Associate Professor of Pediatrics at The Children's Hospital at Montefiore. Listen to the episode now!Click here to claim your free CME/NCPD credit for this activity: https://bit.ly/4eQSbaL
Combating Health Disparities Through More Equitable Screening: Chyke Doubeni, MD, MPH by i3 Health
Multicancer Early Detection - What's Your Opinion? with Chyke Doubeni, MD, MPH by i3 Health
Biomarker Documentation in the Community Setting and Clinical Decision Support: Daniel Rubin, PharmD by i3 Health
Community Oncology Pharmacists - Their Crucial Role and Clinical Impact: Andrea Roman, PharmD, BCOP by i3 Health
Cancer + Careers - Empowering People with Cancer to Thrive in the Workplace: Rebecca Nellis, MPP by i3 Health
Exploring Association of FGFR3 Alterations in Urothelial Cancer: Arlene Siefker-Radtke, MD by i3 Health
Representing Symptom Research and Nursing at ASCO: Natalie Jackson-Carroll, PhD, APRN, FNP-C by i3 Health
Worth the Wait - Supporting Young Adult Cancer Survivors on the Path to Parenthood: Mike Scherer by i3 Health
Optimizing Sacituzumab Govitecan Tolerability in TNBC With Early Management: Antonio Llombart, MD by i3 Health
Investigating Axicabtagene Ciloleucel for R/R Central Nervous System Lymphoma: Lakshmi Nayak, MD by i3 Health
Understanding Lung Cancer Diagnostic Trends to Inform Therapeutic Development: Jess Paulus, SCd by i3 Health
Intuitively Designing Clinical Trials to Empower Patients: Ishwaria Subbiah, MD by i3 Health
Updated Results from the SPOTLIGHT and EV-302 Trials at ASCO: Ahsan Arozullah, MD, MPH by i3 Health
At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Erica Fortune, PhD, Vice President of Research at Cancer Support Community, to discuss her team’s poster entitled, “Head and Neck Cancer (HNC) Survivors: Long-Term Nutrition Impact Symptoms, Eating Problems, and Barriers to Care Impact Psychosocial Health.”In this podcast, Dr. Fortune delves further into this topic, including:Background about long-term side effects and quality-of-life impacts experienced by HNC survivorsCancer Support Community’s survey designed to further investigate these challengesThe results that the study found regarding nutrition, eating problems, and barriers to care that survivors experienceHow Cancer Support Community plans on using the survey results to improve survivorship and address psychosocial impacts experienced by long-term HNC survivorsA preview of other topics that Cancer Support Community is excited to cover as a member organization of the Oncology Data Advisor Editorial BoardAnd more!
At the conclusion of this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, Monzr Al Malki, MD, an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, sat down with Richa Thakur, a Palliative Care Physician and Hematology/Oncology Fellow at Zucker School of Medicine at Hofstra/Northwell Health, to discuss his oral abstract presentation entitled “Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.”
This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. Check out the episode to hear more about: •Qure.ai’s mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI•Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps•Qure.ai’s end-to-end AI-powered solutions for early lung cancer detection and care•The efficacy of these solutions and how they can be used in the clinic•The lung cancer portfolio that Qure.ai showcased at ASCO•Other innovations coming down the pipeline•And more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!
An Innovative Wellness and Professional Development Curriculum for Fellows: Thejal Srikumar, MD by i3 Health
Implementing a Novel Research Methods Training Curriculum for Fellows: Noha Sharafeldin, MD, PhD by i3 Health
Understanding Cardiac Risks of BTK Inhibitors in Hematologic Cancers: Muhammad Salman Faisal, MBBS by i3 Health
The Fellow on Call and Fellowship Research at ASCO: Ronak Mistry, DO, and Vivek Patel, MD by i3 Health
Assessing Risk of Myelosuppression With PARP Inhibitors in Prostate Cancer: Karan Jatwani, MBBS by i3 Health
Representing Fellows in Evidence-Based Wellness Interventions With Andrew Hearn, MD, MSCI by i3 Health
The Sarcoma Foundation of America: Waqas Haque, MD, MPH, and Brandi Felser by i3 Health
The Fellows Forum Live from ASCO 2024: Sam Kareff, Waqas Haque, and Matt Hadfield by i3 Health
Artful Oncology - A Psychosocial Oncology Curriculum for Heme/Onc Fellows: Jafar Al-Mondhiry, MD by i3 Health
In this video, Dr. Catherine M. Broome, Professor of Medicine at Georgetown University Medical Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Putting the Freeze on Cold Agglutinin Disease (CAD). Dr. Broome shares insights into resources she recommends for patients with CAD, the role of thromboprophylaxis, treatment advances to expect within the next year, the most important things for primary care providers and non-hematologists to know about CAD, and more!
In this video, Dr. Jamie E. Chaft, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Leveraging the Growing Arsenal of Therapies for Early-Stage Non–Small Cell Lung Cancer (NSCLC), chaired by Dr. Helena Yu. Dr. Chaft shares insights into emerging roles of measurable residual disease (MRD) in lung cancer, the significance of the recent approval of alectinib for ALK-positive disease, treatment considerations for older versus younger patients, important research updates at the American Society of Clinical Oncology (ASCO) Annual Meeting, and more!
Last year, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, served as co-chair of i3 Health’s webinar and online activity, Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC). With numerous advances in TNBC research occurring since then, Dr. Tolaney sat down with Oncology Data Advisor to share additional updates from clinical trials and a preview into the future of treatment with emerging therapies for TNBC.
A Precision Health Approach Post-Treatment Comorbid Diabetes in Cancer With Marilyn Hammer by i3 Health
Starting the Conversation: End-of-Life Communication in Oncology Nursing With Stacey Simons by i3 Health
Climate Change and Healthcare: What We Can Do To Help - AnnMarie Walton, Ryne Wilson, Stacy Stanifer by i3 Health
Incorporating Patient-Reported Outcomes in Oncology Research: Elaine Novakovich and Theresa Yu by i3 Health
Food for Thought: Nutrition in Vulnerable Cancer Populations With Mariah Jackson and Caitlin Benda, by i3 Health
OurBrainBank: Creating Change in Glioblastoma Treatment With Kelli Duprey and David Robles by i3 Health
Supporting Nurses Returning to Work After Cancer Diagnosis With Kai-Lin You by i3 Health
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
This playlist features live interviews recorded by Oncology Data Advisor at the 49th Annual Oncology Nursing Society (ONS) Congress in Washington, DC. For more information, visit OncData.com.
Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myelomaLive or Virtual Meeting Series: https://www.i3health.com/live/hemonc-fellows-lecture-series-leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma
In this video, Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine, Co-Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center, and Disease Team Leader–Head and Neck at UC San Diego Moores Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: New Insights and Real-World Evidence for Improved Patient Outcomes. Dr. Sacco shares insights into targeted mutations to test for, recommendations for patient education, the future of HPV therapeutic vaccines, monitoring for immune-related adverse events, and more!Claim free CME/NCPD credit for Dr. Sacco's activity here: https://www.i3health.com/course-information/recurrent-and-metastatic-hnscc-new-insights-and-real-world-evidence-for-improved-patient-outcomes
In this video, Dr. Neal Weinreb, Voluntary Associate Professor for Human Genetics at the University of Miami Miller School of Medicine, answers questions asked by the audience during his CME/NCPD–approved activity with i3 Health, Exploring Treatment Advances for Acid Sphingomyelinase Deficiency (ASMD) in Adults. Dr. Weinreb shares insights into screening for lysosomal storage disorders, genetic carrier testing, resources for family and caregivers, the future of treatment with olipudase alfa, and more. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/exploring-new-treatment-advances-for-acid-sphingomyelinase-deficiency-in-adultsLive or Virtual Meeting Series: https://www.i3health.com/live/exploring-new-treatment-advances-for-acid-sphingomyelinase-deficiency-in-adults-1
In this installment of Oncology Data Advisor's Exploring Artificial Intelligence in Oncology series, Dr. Waqas Haque, Fellows Forum member and incoming Hematology/Oncology Fellow at the University of Chicago, speaks with Tracey Sikora, Co-Founder of Every Cure, a nonprofit organization whose mission is to repurpose existing FDA-approved drugs for other indications, especially in rare diseases. Check out the discussion to learn more about: •Challenges in finding treatments for rare diseases, including sparse data, low patient numbers, and lack of financial incentive for pharmaceutical companies•Every Cure’s mission to unlock the potential of drugs that are already on the market•Harnessing the latest AI and machine learning technology to structure data in a biomedical knowledge graph, looking at drugs, diseases, pathways, and targets•Barriers in drug repurposing, including clinical validation and eventual approval•The Advanced Research Projects Agency for Health (ARPA-H) grant and the importance of federal funding for rare disease research•How to develop efficient clinical trials without a large sample size•The future of AI-enabled drug discovery in oncology •And more!
In honor of Acute Myeloid Leukemia (AML) Awareness Day, Oncology Data Advisor Editorial Board and Fellows Forum members Tristan Knight, MD, FRCPC, Richa Thakur, MD, and Joseph Kalis, PharmD, BCOP, hosted a live panel discussion covering the evolving treatment landscape for AML, including: •Novel therapies and combinations such as chimeric antigen receptor (CAR) T-cell therapy and isocitrate dehydrogenase (IDH) inhibitors•The role of measurable residual disease (MRD) testing•Considerations for pediatric transplant and cellular therapy•Words of hope for patients undergoing treatment for AMLAdditionally, they answered live questions from the audience, including: •Do you have any first-line treatment recommendations for patients with a KMT2A mutation? •When do recommend that patients participate in a clinical trial? Take a listen to hear the panelists’ answers to these questions and their perspectives on the ever-changing therapeutic landscape for AML!
In honor of Testicular Cancer Awareness Month, Oncology Data Advisor Fellows Forum members Samuel Kareff, MD, MPH, Waqas Haque, MD, MPH, and Matthew Hadfield, DO, sat down to discuss improving early detection, minimizing toxicities of treatment, and optimizing long-term survivorship, particularly for adolescent and young adult (AYA) survivors of testicular cancer.
In celebration of Head and Neck Cancer Awareness Month this April, Oncology Data Advisor Fellows Forum and Editorial Board Members Samuel Kareff, MD, MPH; Matthew Hadfield, DO; and Nagashree Seetharamu, MD, sat down to discuss the epidemiology of head and neck squamous cell carcinomas (HNSCC), the diagnostic and treatment process of HNSCC, including:–Epidemiologic trends–Geographic distribution–Approved screening methods–Novel treatment combinations–Side effects and adverse events–Survivorship–And more!
This April, Oncology Data Advisor is raising awareness for Esophageal Cancer Awareness Month. In this interview, Oncology Data Advisor Editorial Board and Fellows Forum members Dr. Joseph Kalis, Dr. Matthew Hadfield, and Dr. Samuel Kareff discuss rising trends, treatment advances, and emerging management strategies for esophageal cancer, including the following: •The rising rate of adenocarcinoma in the context of pre-existing esophageal dysplasia and Barrett esophagus•Risk factors such as tobacco and alcohol•The roles of healthy eating and smoking cessation in esophageal cancer prevention •How the rise of immunotherapies such as pembrolizumab, nivolumab, and trastuzumab have changed practice•This month’s approval of fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2 (HER2)–positive solid tumors•Lifestyle interventions such as following the Mediterranean diet and United States Preventive Services Task Force (USPSTF) exercise guidelines that can make maximize tolerability of therapy
In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute. At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including: •The study design, which includes triple-class–refractory patients•The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience•The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients•Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections•The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation•And more!
In this interview, Jason Mouabbi, MD, an Oncology Data Advisor Editorial Board Member and Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, sat down with Valerie Brutus, MD, FACS, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, and Elizabeth Stirling Craig, MD, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, to discuss improving breast cancer surgical outcomes with lymphovenous bypass surgery.Dr. Mouabbi engages Dr. Brutus and Dr. Craig in a thought-provoking discussion about lymphovenous bypass surgery: what it is, who qualifies for this procedure, its viability, what to expect from this procedure and its treatment process, and more about breast cancer surgical outcomes.
Adolescent and Young Adult (AYA) Cancer Awareness Week, April 1 to 5, 2024, is a time to shine a spotlight on adolescent and young adult cancer patients and survivors. To commemorate the week, Lauren Ghazal, Megan-Claire Chase, and Allison Rosen, all members of the Oncology Data Advisor Editorial Board, sat down for a conversation to highlight the issues that AYA cancer patients face, including fertility preservation and financial toxicity; the need to ensure that race, ethnicity, and sexual orientation are not overlooked when building welcoming support spaces for all patients; and the value of turning to the AYA community for support while also serving as your own best advocate.
Dr. Christopher Lieu, Associate Director of Clinical Research at the University of Colorado Cancer Center and Vice Chair of the National Comprehensive Cancer Network (NCCN), is currently serving as chair of i3 Health's online activity, live webinar, and meeting series, Hitting the Target in HER2-Positive Metastatic Colorectal Cancer. With numerous research advances occurring in this field during the past year, Dr. Lieu sat down with us again to share updates in targeted therapies for HER2-positive metastatic colorectal cancer and the evolving landscape of biomarkers under investigation for this disease.Click the links below for Hitting the Target in HER2-Positive Metastatic Colorectal Cancer, an accredited CME/NCPD activity provided by i3 Health!Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/hitting-the-target-in-her2-positive-metastatic-colorectal-cancerLive Webinar Registration: https://www.i3health.com/course-information/Colorectal-Cancer-WebinarLive or Virtual Meeting Series: https://www.i3health.com/live/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer-1
In this edition of the Oncology Data Fellows Forum in celebration of National Doctor's Day, Samuel Kareff, MD, MPH, and Matthew Hadfield, DO, discuss the highs and lows of working in this field and why it is important to take a moment to celebrate being a physician, your fellow physicians, and your patients.
In this edition of Oncology Data Advisor celebrating Kidney Cancer Awareness Month Dr. Samuel Kareff, Dr. Waqas Haque, and Dr. Ulka Vaishampayan discuss the rising incidence of kidney cancer, warning signs and symptoms to look out for, environmental risk factors such as tobacco use, emerging treatment strategies using immunotherapy and adjuvant therapy, considerations for genetic testing, and the importance of clinical trial participation for bringing these new advances to the forefront of care.
In this edition of "Bridging the Gap in Cancer Care Through Genetic Counseling," Editorial Member Catherine Skefos speaks with her colleague Julie Moskowitz, MS, Genetic Counselor in the Gastrointestinal (GI) Center at MD Anderson Cancer Center, about hereditary aspects of colorectal cancer, how she counsels patients and families regarding their risk of colorectal cancer and related syndromes, and how genetic testing can be used to inform screening decisions and ultimately reduce patients' risk.
In this panel discussion in honor of International Women's Day on March 8, Dr. Richa Thakur, Dr. Nida Khan, Dr. Lauren Ghazal, and Dr. Gurbakhash Kaur discuss their perspectives as women in the fields of medicine and nursing, including their advice for negotiating, seeking mentors, overcoming imposter syndrome, building confidence, and making your voice heard.
Dr. Spero Cataland, Professor of Internal Medicine and the Benign Hematology Section Head at The Ohio State University, Wexner Medical Center, is currently serving as chair of i3 Health's free CME/NCPD activity and Hematology Fellows Lecture Series, Current Standards and New Directions in Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). In this interview, Dr. Cataland provides an update on new research that has occurred in the field during the past year and shares a preview of what learners can look forward to when attending his presentation at their own institution.
In this interview for Kidney Cancer Awareness Month, Hiam Abdel-Salam, MS, CGC, speaks with Donika Saporito, MS, a Certified Genetic Counselor in the Genitourinary Center at MD Anderson Cancer Center, who provides an overview of genetic testing for hereditary kidney cancer syndromes and how she personally counsels the patients she sees.
Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education (CME)–/nursing continuing professional development (NCPD)–approved virtual tumor board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma, alongside Kathleen Polson, Nurse Practitioner at Dana-Farber Cancer Institute, and Shreyaskumar R. Patel, MD, Center Medical Director of the Sarcoma Center at MD Anderson Cancer Center.In this interview, Dr. Rubin sat down with Oncology Data Advisor to discuss updates in the treatment and management of soft tissue sarcoma, what to look forward for the future of treating sarcomas, and his passion for this field.
For Multiple Myeloma Awareness Month this March, Oncology Data Advisor hosted a live panel discussion geared towards patients living with multiple myeloma. Dr. Rahul Banerjee, Dr. Alankrita Taneja, Dr. Richa Thakur, and Dr. Gurbakhash Kaur helped put the myriad of new developments in multiple myeloma treatment into perspective for patients and answered questions from the audience regarding current and future treatment strategies for multiple myeloma.
Last year, Jaffer Ajani, MD, Professor in the Department of Gastrointestinal (GI) Medical Oncology at MD Anderson Cancer Center, served as co-chair of i3 Health's Virtual Tumor Board, Building Comprehensive Care Plans in Esophagogastric Cancers, along with Lei Zhao, MD, PhD, Assistant Professor of Pathology at Brigham and Women's Hospital, and Kelly Rone, DNP, RN, AGNP-c, Advanced Practice Nurse at the Mayo Clinic. With numerous developments in the field occurring since recording the activity, Dr. Ajani sat down with Oncology Data Advisor to provide an update on the evolving field of esophagogastric cancer research and advances to look forward to in the coming years.
In this first episode of Oncology Data Advisor’s new podcast series, “Bridging the Gap in Cancer Care Through Genetic Counseling,” Hiam Abdel-Salam and Catherine Skefos provide an introduction to genetic counseling, including how they entered the field, what they do on a day-to-day basis, scenarios in which patients should or should not consider meeting with a genetic counselor, things that are covered in an appointment, and their favorite parts about working as genetic counselors.
Following the recent approval of lifileucel for unresectable or metastatic melanoma—the first cellular therapy to receive an approval for solid tumors—Matthew Hadfield, DO, member of the Oncology Data Advisor Fellows Forum and third-year Fellow at Brown University, sat down with Richard Carvajal, MD, Oncology Data Advisor Editorial Board Member and the Deputy Physician-in-Chief at the Northwell Health Cancer Institute, to discuss the significance of this approval, what it means for the treatment landscape of melanoma, and what to look forward to for the future of treating melanoma.
In celebration of Women's Day on March 8, Oncology Data Advisor hosted a live panel discussion in which the women of our Editorial Board and Fellows Forum share what the day means to them, progress that has been made in female representation in leadership roles, continued obstacles to overcome, and the value of encouraging and mentoring other women in the field.
In this Fellows Forum interview, Dr. Samuel Kareff speaks with Dr. Estela Rodriguez, Clinical Research Lead of the Thoracic Site Disease Group at the University of Miami Sylvester Comprehensive Cancer Center, about recent research advances in mesothelioma, the emerging roles of immunotherapy and biomarker testing, and the importance of ensuring access to care for patients with this rare disease.
On Rare Disease Day on February 29, members of the Oncology Data Advisor Editorial Board and Fellows Forum hosted a live panel discussion focused on the rare diseases that they treat, including tireless efforts underway to develop novel treatment strategies, enhance quality of life, and improve outcomes for patients.
In this interview, Joseph Kalis, PharmD, BCOP, introduces Joseph Oropeza, PharmD, BCCP, one of the newest Editorial Board members of Oncology Data Advisor. Dr. Oropeza shares what he does as an Emergency Medicine Pharmacist, the intersections of oncology and the emergency department, the steps he takes to manages oncologic emergencies, and the importance of communication and collaboration between disciplines to ensure optimal outcomes for patients.
In honor of Colorectal Cancer Awareness Month this March, Allison Rosen, MS, and Matthew Hadfield, DO, members of the OncData Editorial Board and Fellows Forum, sat down to discuss their perspectives on the month from both the clinical and survivorship viewpoints, including efforts to advocate for increased clinical trial funding, recent updates in research and treatment, and messages for both patients and the public about the importance of screening and raising awareness.
In this installment of Oncology Data Advisor's Exploring AI in Oncology series, Dr. Waqas Haque speaks with Dr. Shaalan Beg, an Adjunct Associate Professor at the University of Texas (UT) Southwestern, who is spearheading efforts to decentralize clinical trials in oncology and expand access for eligible patients. Dr. Beg describes the tools that are currently in development for decentralizing trials, including the use of artificial intelligence (AI), natural language processing, and telehealth. Additionally, he shares his perspectives on transitioning to a career in industry.
On February 14, Oncology Data Advisor is celebrating National Donor Day and recognizing the contributions of individuals who have given organ and tissue donations for patients in need. In this interview, Fellows Forum member Dr. Richa Thakur has a conversation with Will Smith, a High School History Teacher, who gave an anonymous stem cell donation through Be the Match (the National Marrow Donor Program, NMDP) in 2015.
In this interview, Dr. Jason Mouabbi, OncData Editorial Board Member and Breast Medical Oncologist at MD Anderson Cancer Center, speaks with Dr. Ross Maclean and Michael Glover about the debate surrounding accelerated FDA approvals, including their benefits, risks, and ways that physicians, patients, pharmaceutical companies, and the FDA can collaborate to maximize the impact of accelerated approval drugs.
In honor of National Cancer Prevention Month 2024, members of the Oncology Data Advisor Editorial Board and Fellows Forum sat down for a panel discussion about the rising incidence of cancer diagnoses, factors contributing to them, and how to counsel patients in light of these emerging trends.
In this Fellows Forum interview, Samuel Kareff, MD, MPH, interviews Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, about how he became involved in neuroendocrine cancer research, the latest developments in novel therapies, and the future of using radiopharmaceuticals and theranostics to revolutionize the treatment of neuroendocrine tumors.
In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular testing, clinical trial diversity, and patient advocacy worldwide.
In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.
In honor of National Cancer Prevention Month, Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, sat down with Dr. William Aronson, Professor of Urology at the University of California, Los Angeles (UCLA) and Chief of Urologic Oncology at the West Los Angeles Veterans Affairs (VA) Medical Center for a conversation about the multitude of factors under investigation for prostate cancer prevention. Dr. Freedland and Dr. Aronson discuss prostate-specific antigen (PSA) screening recommendations, medications being investigated, the roles of diet and exercise, and how they personally counsel their patients regarding prostate cancer prevention and risk reduction.
At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment! Free CME activity: https://www.i3health.com/course-information/expert-guidance-on-current-standards-and-new-directions-in-newly-diagnosed-multiple-myelomaBook a meeting for your institution: https://www.i3health.com/live/expert-guidance-on-current-standards-and-new-directions-in-newly-diagnosed-multiple-myeloma-1
This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.
Recently, the FDA granted approval to capivasertib in combination with fulvestrant for patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations. In this interview, Editorial Board member Dr. Jason Mouabbi speaks with Dr. Carlos Doti, Head of Medical Affairs, US Oncology at AstraZeneca, about the significance of the approval, its dosing schedule, AstraZeneca's approach towards patient education and adverse event management, and the future of capivasertib in different treatment settings.
At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of health among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). In this interview, he further discusses how the treatment landscape of CLL/SLL has changed with the introduction of BTK inhibitors and his next steps for this research.
Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In this interview, Dr. Zeidan further delves into his research and what it could mean for the future treatment landscape of MDS.
Recently, Genmab and AbbVie announced updated results of the phase 1/2 EPCORE™ NHL-1 clinical trial of epcoritamab (epco) for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Matthew Hadfield and Dr. Alankrita Taneja of the Oncology Data Advisor Fellows Forum speak with Dr. Tahi Ahmadi, Chief Medical Officer at Genmab, and Dr. Jacqueline Nielsen, Therapeutic Area Head for Hematology at AbbVie, about the significance of these results, the benefits of epcoritamab's subcutaneous administration, management of adverse events, and the future role of epcoritamab in the treatment landscape for follicular lymphoma.
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!
In this first episode of Oncology Data Advisor’s new podcast series, “Exploring Artificial Intelligence in Cancer Care,” Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients’ probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost’s novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
At the recent San Antonio Breast Cancer Symposium (SABCS), numerous updates were presented which have the potential to improve treatment outcomes for patients with breast cancer. After returning from the meeting, Dr. Jason Mouabbi, Assistant Professor of Breast Medical Oncology at MD Anderson Cancer Center and Editorial Board Member of Oncology Data Advisor, sat down to highlight some of the most exciting research presented, including the HER2CLIMB-02, MONARCH 3, and INAVO trials.
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!
In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Adrian Mosquera, Clinical Hematologist at the University Hospital of Santiago de Compostela, about his research team’s novel machine learning model that incorporates patient characteristics and histological subtype into risk prognostication for mantle cell lymphoma (MCL). In addition, Dr. Mosquera shares more of his research utilizing artificial intelligence for designing more risk-tailored therapeutic approaches and facilitate personalized medicine in hematologic malignancies.
Recently, the American Cancer Society recommended new lung cancer screening guidelines to shift the focus from quitting smoking, to helping all individuals who have smoked despite quitting 20 to 30 years prior. In this interview, Dr. Brian Whang, Medical Director of Lung Cancer Screening for Hartford Healthcare, discusses these new guidelines, what they mean, and why we should continue advocating for better lung cancer screening guidelines and awareness of this issue.
In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer Institute, about his recent publication of the TALAPRO-2 study. Dr. Agarwal delves into the results of the trial, which investigated the efficacy of talazoparib plus enzalutamide for first-line metastatic castration-resistant prostate cancer (mCRPC), and their practice-changing significance.
Recently, Sepideh Gholami implemented a Hepatic Artery Infusion Pump Program at Northwell Health. In this interview, Dr. Gholami discusses what exactly a hepatic artery infusion pump is, its benefits, and how it will affect the future treatment landscape of cancers as a whole. As well, she advocates for the implementation of these programs in more institutions across the nation.
The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.
Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and shares resources and advice for clinicians working in the field of prostate cancer.
This November, Oncology Data Advisor is honoring Pancreatic Cancer Awareness Month and helping to raise awareness about early detection in hopes of improving outcomes for patients with this disease. In this interview, Oncology Data Advisor Editorial Board member Joseph Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, explains the challenges related to diagnosis and screening, ongoing efforts to develop better detection methods, and messages for both the public and the health care community for maintaining awareness of pancreatic cancer.
In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global perspectives regarding treatment, equity, and patient advocacy in lung cancer.
During National Family Caregivers Month this November, Oncology Data Advisor is celebrating the caregivers of patients with cancer and advocating for increased awareness, support, and education regarding the caregiving experience. In this interview, Megan-Claire Chase, patient advocate and member of the Oncology Data Advisor Editorial Board, shares her experience of being a caregiver for her mother, how her perception has changed before and after her own cancer diagnosis, the importance of prioritizing mental health, and messages for clinicians who seek to provide increased support for their patients' caregivers.
In honor of the Great American Smokeout, Oncology Data Advisor sat down with Stephen Freedland, MD, the Director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Medical Center, to discuss the impact that smoking has on prostate cancer, as well as to help raise awareness around smoking and share resources for those who are trying to quit.
During National Family Caregivers Month this November, Oncology Data Advisor is spotlighting not only the caregivers of patients with cancer, but also the oncology nurses who partner with them to help navigate the cancer care journey. In this interview, Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center and OncData Editorial Board member, shares how she helps support and provide education for her patients’ caregivers, as well as resources she recommends for guiding them through the experience.
At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.
On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Fellows Forum joined forces to share recent research in lung cancer diagnosis and screening, the need to address disparities experienced by patients, and ways to raise awareness for patients, the public, and the health care community throughout the month of November. Hear unique perspectives from Waqas Haque, MD, MPH, Internal Medicine Resident at New York University; Samuel Kareff, MD, MPH, Hematology-Oncology Fellow at the University of Miami; and Matthew Hadfield, DO, Hematology/Oncology Fellow at Brown University.
At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.
In this interview, Dr. Nagashree Seetharamu, MD, MBBS, a Professor in the Division of Hematology and Medical Oncology in the Department of Medicine at Hofstra Northwell Health, sat down to discuss the vital role that exercise takes in the cancer treatment and recovery process. As well, she shares advice on why an individualized approach to a patient’s exercise routine and care is crucial to their survivorship.
This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) meetings.
At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metastatic triple-negative breast cancer (TNBC). In this interview, he gives us further insight to the results he shared and what these results could mean for the future of the TNBC treatment landscape.
In this interview, Dr. Joseph Kalis, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, speaks with i3 Health and the Pharmacy Podcast Network to share an exclusive preview of the recent CPE activity that he developed with i3 Health, Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma. After the interview, stay tuned to hear the full presentation from Dr. Kalis and his co-chair, Dr. Eric Cannon, Chief Pharmacy Benefits Officer at SelectHealth, and claim free CPE credit for the activity at https://bit.ly/45WA5hR. -----DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIESi3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) endorse the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) does not endorse any products or services.Relevant financial relationships exist between the following individuals and ineligible companies:The i3 Health planners, reviewers, and managers have nothing to disclose.St. John Fisher University Wegmans School of Pharmacy (WSOP) staff members have no relevant financial relationships to disclose.Eric Cannon, PharmD, FAMCP, has no relevant financial relationships to disclose.Joseph A. Kalis, PharmD, BCOP, has no relevant financial relationships to disclose.i3 Health has mitigated all relevant financial relationships.
For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.
In this interview, Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, shares the results of the innovaTV 301 trial of tisotumab vedotin for patients with recurrent or metastatic cervical cancer, which were recently presented at the European Society for Medical Oncology (ESMO) 2023 Congress.
In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share their passions for cancer research, discuss the recent and upcoming progress in their respective areas of study, and raise awareness for the tireless efforts being undertaken to advance cancer research.
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health’s CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC. At the end of the interview, stay tuned to hear Dr. Park's full presentation and claim credit at https://www.i3health.com/course-information/video-viewpoint-strategy-session-optimizing-treatment-selection-sequencing-and-tolerability-in-small-cell-lung-cancer.
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health’s CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC.
In this Oncology Data Advisor Fellows Forum interview, Dr. Matthew Hadfield, Medical Oncology Fellow at Brown University, and Dr. Richa Thakur, Hematology/Oncology Fellow at Northwell Health, explore the different types of educational opportunities available during fellowship, including podcasts and in-person meetings, and strategies for finding the most up-to-date education.Visit https://i3health.com/new-cme/cme-meetings-for-institutions to explore the FREE live hematology/oncology meeting series offered by i3 Health, and book one for your institution today!
In honor of Blood Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Dr. Rahul Banerjee sat down with Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center, to discuss updates and the advantages and disadvantages of different dosing schedules for treating multiple myeloma.
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.
In this Oncology Data Advisor Fellows Forum Interview, Dr. Matthew Hadfield, third-year Hematology/Oncology Fellow at Brown University, shares a comprehensive timeline of the history of immunotherapy and its emerging role in cancer treatment. Additionally, he shares considerations for the differential diagnosis of immunotherapy-related adverse events, timely management for providing optimal efficacy outcomes, and the importance of keeping immunotherapy-related toxicities on the radar for clinicians of all specialties and types of practice.
In this interview for Breast Cancer Awareness Month, Dr. Connie Visovsky, Professor and Endowed Chair in Nursing Science at the University of South Florida, shares her research regarding exercise as a self-management strategy for chemotherapy-induced peripheral neuropathy (CIPN) experienced by patients during breast cancer treatment. Additionally, she gives an update on her presentation from last year's ODACon Breast Cancer Symposium regarding new directions in research for CDK4/6 inhibitors.
At the 2023 Oncology Nursing Society (ONS) Bridge Conference, Dr. Lauren Ghazal, Assistant Professor in the School of Nursing at the University of Rochester Medical School and Oncology Data Advisor Editorial Board member, gave the keynote presentation entitled "Finding Your Why." Afterwards, she sat down to share further insights into the presentation, advice for nurses who are reflecting upon their "why" at different stages of their career, and how asking this question will not only help nurses to build fulfilling careers but to also strengthen nursing sustainability on a larger scale.
In this interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, provides insightful answers to frequently asked questions and debunks common myths surrounding breast cancer diagnosis, screening, and treatment.
For individuals with breast cancer, financial toxicity is a significant and often overwhelming part of the fight. Pink Fund is an organization which provides 90-day non-medical cost-of-living expenses, including housing, transportation, utilities, and insurance costs, for patients undergoing active treatment for breast cancer, enabling them to focus on healing before returning to the workplace. In this interview, Pink Fund's Founder, Molly MacDonald, shares the story of how she founded the organization, resources for both patients who are experiencing financial toxicity and for clinicians seeking to support their patients, and crucial messages for raising awareness of financial toxicity during cancer treatment.
In this panel discussion, Oncology Data Advisor and MedNews Week join forces to discuss the power of holding interdisciplinary conversations in oncology and the value of bringing together individuals from diverse backgrounds, locations, career stages, and specialties to share their perspectives on oncology practice and disseminate their knowledge to others in the field.
In this interview, Marcus Engel, MS, CXCP, CSP, a renowned health care author and speaker, sat down with Oncology Data Advisor to share his personal experiences of receiving compassion in the health care system, its implication for patient care, and ways that medical professionals can embrace compassion and integrate it into their practice.
In honor of Take a Loved One to the Doctor Day, Beth Sandy, MSN, CRNP, an Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, and Editorial Board Member at Oncology Data Advisor, sat down to discuss the importance of advocating for our loved ones to regularly visit the doctor, keeping up with screening and treatment, and navigating the guilt felt when a loved one is diagnosed.
At the International Myeloma Society (IMS) 2023 Annual Meeting and Exposition, Dr. Madhav Dhodapkar, Director of the Cancer Center at Emory University, presented the results of the LINKER-MM1 trial of linvoseltamab for relapsed/refractory multiple myeloma. Here, he further delves into the efficacy of linvoseltamab observed in the trial and its projected place in the treatment landscape.
Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Editorial Board member Dr. Richard Carvajal, Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute in New York, discusses the approval and the trial that led to it, as well as share exciting insights on the potential future landscape of this rare disease.
In honor of World Cancer Research Day, Dr. Waqas Haque, a third-year Internal Medicine Resident at New York University (NYU) and Oncology Data Advisor Fellows Forum member, shares advice for residents and fellows who are interested in becoming involved in oncology research. Dr. Haque offers practical tips for finding a mentor, identifying and exploring a research topic, making time for projects amidst a busy schedule, balancing research with patient care, and much more.
This interview features Oncology Data Advisor Fellows Forum member Dr. Nida Khan, a Medical Oncology and Palliative Care Fellow at The Ohio State University, and Editorial Board member Dr. Joseph Kalis, Ambulatory Oncology Pharmacy Specialist at the University of Colorado Health, in a multidisciplinary conversation for Pain Awareness Month. Dr. Khan and Dr. Kalis explain the different types of pain trajectories, particularly for patients with cancer, and the unique ways in which they approach pain management in their different specialties.
In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, sat down to discuss the importance of bringing awareness to prostate cancer, up-to-date diagnostic techniques, and updates in therapeutic selection and treatment.
This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.
This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.
In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.
This Oncology Data Advisor Fellows Forum interview celebrates National Immunization Awareness Month, featuring Richa Thakur, MD, Hematology/Oncology (Heme/Onc) Fellow at Northwell Health, and Waqas Haque, MD, Internal Medicine Resident at New York University, in a discussion about the importance of immunizations for cancer patients, their friends and family, and in general, as well as advice for clinicians on approaching the topic of immunizations with their patients.
Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.
In this interview, Ofer Sharon, MD, the CEO of OncoHost, explains the unique opportunities for harnessing precision medicine in oncology, the unmet needs regarding biomarker development, and the potential of utilizing a multicomponent biomarker approach for understanding the mechanisms of therapy resistance and developing novel pathways for treatment.
In this interview, Swathi Varanasi, PharmD, an integrative health pharmacist, shares her passion for incorporating wellness and natural medicine into pharmacy practice, including her pathway to studying integrative health, its specific roles for helping patients with cancer achieve their goals, and ways that pharmacists and other health care professionals can begin to utilize these methodologies in their practice.
EXPIRING ON MONDAY, AUGUST 21!
In this podcast from i3 Health gain expert insight and enhance your clinical knowledge with this case-based activity focusing on new and groundbreaking biomarkers used for diagnosis of graft-versus-host disease, factors for therapy selection, and clinical trial findings used to individualized treatment for patents, presented by leading faculty Shernan Holtan, MD, Associate Professor of Medicine, University of Minnesota, and Carrie Kitko, MD, Associate Professor of Pediatrics, Vanderbilt University Medical Center. Start the activity now!
Click here to claim CME/NCPD/CPE credit: i3health.com/oda-gvhd
Megan-Claire Chase, a patient advocate and invasive lobular breast cancer survivor, recently appeared on the "Beyond Cancer" Episode of PBS's Stories from the Stage. In this interview, Ms. Chase shares more about the experience and the important messages for patients, survivors, and clinicians that she hoped to convey in her talk and throughout her advocacy.
This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now!
Click here to claim you free CME/NCPD credit: https://bit.ly/3OFBxiX
Presented by Dr. Shawn Kwatra, Director, Johns Hopkins Itch Center, Associate Professor of Dermatology, Johns Hopkins University School of Medicine and Dr. Linda Stein Gold, Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System, this expert led discussion will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease.
Click here to claim credit: i3health.com/atopic-dermatitis
This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.
i3 Health is pleased to be hosting Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, a live webinar, on July 12, 2023 at 1:00 pm EST, chaired by Dr. Sara Tolaney and Dr. Ira Bleiweiss. In this video interview, Dr. Tolaney shares a preview of the important topics she will be discussing in the webinar, including approaches to treatment selection, the emerging role of novel therapies, timely management of adverse events, and much more. Watch the video to gain insight into the factors Dr. Tolaney takes into account in the management of TNBC, and register for the webinar on July 12 to hear the complete discussion!
In this Oncology Data Advisor® Fellows Forum interview, member Waqas Haque, MD, an Internal Medicine Resident at New York University, shares his medical training journey, the research he has conducted as Clinical Investigator Track Resident, his plans for applying to an oncology fellowship, advice for navigating the experience, tips for acquiring oncology exposure during residency, and much more!
In this Oncology Data Advisor® Fellows Forum interview, Richa Thakur, MD, Hematology/Oncology Fellow at Northwell Health, speaks with Nida Khan, MD, a third-year Internal Medicine Resident who is beginning a joint Medical Oncology and Palliative Care Fellowship this July. Dr. Khan discusses the unique opportunities provided by this new type of fellowship, her passions for palliative care and global health, and advice for navigating the fellowship application process to find your niche in the program that is the best fit for you.
Following the recent 48th Oncology Nursing Society (ONS), Terri Armstrong, the Senior Investigator and Deputy Chief of the Neuro-Oncology Branch at the National Institutes of Health (NIH), sat down with Oncology Data Advisor® to further discuss her translational research regarding better understanding and improving the quality of life of cancer patients.
Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Richard Newcomb, MD!
Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Timothy Cloughesy, MD!
Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Thomas Hutson, MD!
Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Stephanie Smith, MD!
Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Dr. Shubham Pant!
Listen to this live interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Allison Rosen!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Yan Leyfman, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Robin Lally and Marilyn Hammer!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting With Stephen Freedland, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting With Dr. Thomas Abrams, MD, Editor in Chief of Oncology Data Advisor!
In this podcast episode, Nina Morena, MA, PhD Candidate at McGill University, and Ari Meguerditchian, MD, Surgical Oncologist at McGill University Health Center, sit down to talk about Ms. Morena’s thesis topic and research, How reliable are post-mastectomy breast reconstruction videos on YouTube?, which she presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Her presentation encompasses the effects of social media platforms, specifically YouTube, on breast cancer patients.
In May 2023, the FDA granted approval to epcoritamab, a CD3-redirecting, CD20-targeting bispecific antibody, for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. Following the approval, Oncology Data Advisor® spoke with Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Institute and one of the investigators of the EPCORE NHL-1 trial, on which the approval was based, to learn more about the efficacy and safety of epcoritamab and its burgeoning role in the treatment of relapsed/refractory DLBCL.
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Michael Halpern, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Noelle Cloven, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Nicholas Robert, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Nicholas Phillips, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Michael Halpern, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Manoj Bupathi, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Mandi Pratt-Chapman, PhD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Lalan Wilfong, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Kohei Shitara, MD!
Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Kathleen Moore, MD!
In this interview, Oncology Data Advisor® is joined by Dr. Christine Ko, Professor of Dermatology and Pathology at Yale University and host of the See, Hear, Feel podcast. Dr. Ko shares her passion for incorporating cognitive psychology and emotional intelligence into medical practice and explains how doing so can enhance patient encounters and care.
Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting With Jason Westin, MD
Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting With Janet Espirito, PharmD
Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting With Funda Meric-Bernstam, MD
In this Oncology Data Advisor® Fellows Forum Interview, Dr. Richa Thakur, Hematology/Oncology (Heme/Onc) Fellow at Northwell Health, outlines the need for palliative care education in the oncology setting and shares valuable resources for fellows who are interested in expanding their knowledge of palliative care and hospice to better serve their patients.
Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting with Aamir Ehsan, MD, and Bridget Herschap, MD, of CorePath Laboratories!
Listen in to this podcast recorded live at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Barb Kunz, MS, LCGC!
Listen in to this podcast recorded live at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Bradley McGregor, MD!
Listen in to this podcast recorded live at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Cassy Horton!
Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting With Darya Kizub, MD!
Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting With Deepa Rangacharia, MD!
Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting With Erica Feinberg, PharmD!
Click here to view and claim credit for Managing Toxicities of Novel Breast Cancer Therapies: PI3K Inhibitors, an accredited CME/NCPD/CPE activity by i3 Health: i3health.com/odabc-pi3k.Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia and rash. In this interview from the 48th Annual Oncology Nursing Society (ONS) Congress, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke’s Koontz Center for Advanced Breast Cancer, shares updated strategies for managing these toxicities in order to provide the best outcomes for patients with breast cancer receiving PI3K inhibitors.
Click here to view the full activity and claim CPE credit: https://i3health.com/oda-mm-treatment New technologies are leading to deeper responses and longer survival for patients with multiple myeloma. But these complex care plans lead to questions about how to optimize care. Clinicians are challenged with leveraging the best available evidence and meeting individual care needs in diverse patient populations across different settings. In this interview, Joseph Kalis, PharmD, BCOP, provides a preview of a continuing pharmacy education (CPE) activity he recently chaired for i3 Health, "Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma."
At the 48th Annual Oncology Nursing Society (ONS) Congress, Dr. Megan Mullins, an Assistant Professor at the University of Texas (UT) Southwestern Cancer Center, gave a presentation on improving cancer survivorship for sexual and gender minorities. In this follow-up interview, she shares the ongoing efforts into improving cancer survivorship care for these populations, as well as advice and resources for clinicians for creating welcoming spaces for LGBTQ+ cancer patients and survivors.
Listen in to this ONS Congress 2023 podcast featuring Jessica Coviello, DNP, RN, ANP-BC
Click here to claim CME/NCPD credit for this activity: https://i3health.com/oda-gvhd This audio includes both the additional updates interview and complete podcast from i3 Health’s CME/NCPD activity New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease.First, listen along as Dr. Shernan Holtan shares the latest data from the BTM CTN 1703 trial of posttransplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as GVHD prophylaxis after allogeneic hematopoietic cell transplantation, then stay tuned after the interview to listen along to the full activity.
In this interview from the Oncology Nursing Society (ONS) 2023 Congress, Oncology Data Advisor speaks with Lauren Ghazal, PhD, FNP-BC, a Family Nurse Practitioner and Post-Doctoral Research Fellow at the University of Michigan. Dr. Ghazal was honored at ONS Congress as a recipient of the 2023 Mara Mogensen Flaherty Memorial Lectureship Award to discuss "Current Challenges: Nursing Sustainability" along with fellow recipients Suzanne Carroll, RN, MS, AOCN®; Amy E. Rettig, DNP, MALM, MSN, BSN, RN ACNS-BC, PMHNP-BC; and 2000 Mara Mogensen Flaherty Memorial Lectureship Award recipient Debi Boyle, MSN, RN, AOCNS®,FAAN, serving as moderator. In this interview, Dr. Ghazal highlights her inspiring work and research investigating nursing sustainability and cancer survivorship for adolescents and young adults, and shares how to encourage more individuals to pursue a fulfilling career in nursing and research.
Recently, the Oncology Nursing Certification Corporation (ONCC) unveiled its new logo, which embraces the diversity and the passion behind oncology nursing. In this interview, Tony Ellis, MSEd, CAE, ICE-CCP, the Executive Director of ONCC, shares the features of their recently rebranded website and the benefits of obtaining ONCC certification, as well as steps and tips for nurses who are interested in becoming certified.
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Natalie McAndrew, PhD, RN, ACNS-BC, CCRN-K!
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Michi Gray, RN, OCN, and Joscelyn Vanduren, ANP!
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Maria Badillo, MSN, RN, OCN, CCRP!
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Lesley Glenn!
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Kathleen Burns, MSN, NP
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with John Hillson, RN, BSN, OCN!
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Julianna Cebollero, PharmD, BCOP!
Listen in to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Lenora Casey, OCN, BSN-RN!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Doyle Bosque, RN, CNML!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Colleen Stoner and Diane Haley, LCSW!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Colette Baudoin, PhD, RN!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Amy Rettig, DNP, RN, APRN-BC!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Amanda King, PhD, APNP-BC!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Abbey Kaler, APRN, FNP-C!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Janie Metsker, RN!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Elizabeth Archer-Nanda, DNP, PMHCNS-BC, and Meagan Dwyer, PhD!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Nick Escobedo, DNP, RN!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Susan Rux, PhD!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Tammy Triglianos, DNP, ANP-BC, AOCNP!
Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Tanya Uritsky, PharmD!
This interview is the first in a new series spotlighting the Oncology Data Advisor® Editorial Board, featuring Dr. Richard Carvajal, Director of Medical Oncology at Northwell Health Cancer Institute. Dr. Carvajal tells the story of how he became a melanoma researcher and shares his passions for developing targeted therapies for unique clinical subsets of melanoma and for providing high-quality cancer care for patients in their own neighborhoods.
This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, Start the activity now!Click the link to claim your free CME/NCPD credit: https://i3health.com/oda-ec
Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Sunil Iyer, Chief Hematology/Oncology Fellow at the University of Miami, Florida, discusses his leukemia research, exciting new treatment directions, and what to look forward to in the next several years in this field,
Oncology Data Advisor® is excited to announce the launch of the Fellows Forum, a new resource featuring expert perspectives geared toward Hematology/Oncology Fellows. In this interview, Dr. Samuel Kareff, Chief Hematology/Oncology Fellow at the University of Miami's Sylvester Cancer Center, discusses the educational topics that he is looking forward to sharing his insights on as a Fellows Forum member; including tips for fellowship application, specialty pros and cons, research advances, and collaborations with policymakers and patient advocacy groups.
Tune into this interview live from the 48th Oncology Nursing Society (ONS) Congress, in which Tanya Uritsky, the Opioid Stewardship Coordinator at the Hospital of the University of Pennsylvania, discusses her presentation When Pain Holds a Grudge, Give It a Nudge! Best Practices for Managing Chronic Cancer-Related Pain. Her talk encompasses new and novel interventional therapy options and best practices to manage and treat chronic cancer-related pain.
Tune into this interview live from the 48th Oncology Nursing Society (ONS) Congress, in which Elizabeth Archer-Nanda, Founding Member of the Behavioral Oncology Program and Clinical Director of Advanced Practice Providers at Norton Cancer Institute, and Meagan Dwyer, a Licensed Clinical Psychologist, discuss their presentation Compassionate Cancer Care: A Trauma-Informed Approach to Mental and Emotional Patient Health Needs. Their talk encompasses the mental health concerns experienced by cancer patients and how clinicians can apply self-care with a trauma-informed approach.
Tune into this interview live from the 48th Oncology Nursing Society (ONS) Congress, in which Scott Christensen, Senior Nursing Director at the University of Utah, discusses his presentation regarding Safety and Violence in Healthcare. His talk encompasses the trends in workplace violence and potential strategies to prevent such instances to help protect staff.
In this interview for National Minority Health Month, Oncology Data Advisor speaks with Dr. Ian Bouligny, a third-year Hematology/Oncology Fellow at Virginia Commonwealth University (VCU) Massey Cancer Center. Dr. Bouligny shares updates on his research regarding health care barriers faced by patients of minority populations with acute myeloid leukemia (AML) and suggests questions that clinicians can ask their patients to ensure proper treatment support and accessibility.
Click here to claim CME/NCPD/CPE credit for this activity: i3health.com/oda-cinChemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and duration of neutropenia place patients at higher risk of developing febrile neutropenia (FN) and experiencing dose reductions or delays that may compromise the efficacy of chemotherapy (Gargiulo et al, 2021). Additionally, among patients with cancer, hospitalizations related to complications of CIN result in substantial medical costs, in addition to increased morbidity and mortality (Li et al, 2020). Therefore, it is essential that members of the multidisciplinary team have a comprehensive understanding of the risk factors, current clinical practice guidelines, emerging data, and management strategies for CIN. In this activity, Gary Lyman, MD, MPH, and Maura Abbott, PhD, AOCNP®, CPNP, will update clinicians on recent developments in the prevention, treatment, and management of CIN.
In honor of National Minority Health Month, Dr. Shakira Grant, Assistant Professor at the University of North Carolina at Chapel Hill, sat down with Oncology Data Advisor to talk about her research surrounding racial disparities faced by patients with multiple myeloma. Dr. Grant outlines the existing barriers to equitable health care and shares valuable advice on steps that oncology clinicians can take to make health care more accessible for their patients of minority populations.
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Listen now to earn free CME/NCPD!Click here to claim credit: http://bit.ly/3nT8TQJ
At the recent American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Lisa Gudenkauf, an Applied Research Scientist at Moffitt Cancer Center, presented her team's research regarding the Functional Assessment of Cancer Therapy—Radionuclide Therapy (FACT-RNT), a novel patient-reported outcomes (PRO) measure for patients with prostate cancer. In this follow-up interview, Dr. Gudenkauf shares more about how the measure was developed, its importance for capturing the patient experience, and its future implementation into both clinical practice and trials.
Recently, Ravi Parikh, MD, MPP, an Assistant Professor of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania, Perelman School of Medicine, released a research letter titled, “Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.” In this interview with OncData, he further discusses his research and gives a thought-provoking analysis of what these findings could mean for the future of the accelerated approval program, as well as how the multidisciplinary team could better advocate and let their voices be heard for more quality clinical trials.
In honor of Rare Disease Day on February 28, the Oncology Data Advisor Editorial Board held a live panel discussion that featured updates on rare gastrointestinal cancers from Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School; perspectives on nursing management of mantle cell lymphoma from Maria Badillo, Research Nurse Manager at MD Anderson Cancer Center; and updates on rare genitourinary cancers from Dr. Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center.
Click here to view and claim credit for Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/nsclc-immunotherapy Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down with Oncology Data Advisor to provide an update on the rapidly evolving field of NSCLC immunotherapy.
This expert-led episode of the i3 Health podcast, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. Listen now to earn free CME/NCPD!Click here to claim credit: i3health.com/oda-nsclc-immunotherapy
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Just under a year ago, Beth Sandy, a Thoracic Oncology Nurse Practitioner, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in treatment and supportive care strategies since recording.
Click here to view and claim credit for Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/nsclc-immunotherapy Just under a year ago, Beth Sandy, MSN, CRNP, a Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in treatment and supportive care strategies since recording.
This 2-module continuing pharmacy education—(CPE) Strategy Session brings together 2 expert pharmacists to discuss treatment goals and value-based care for patients with newly diagnosed multiple myeloma. Learners must complete both modules to receive credit.In Module 1 of this CPE-approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.In Module 2 of this CPE-approved activity, Eric Cannon, PharmD, FAMCP, Chief Pharmacy Benefits Officer at SelectHealth, will explore strategies for aligning treatment goals and value-based care for patients with newly diagnosed multiple myeloma.Listen now and click here to claim credit: i3health.com/oda-mm-treatment
In 2022, Allison Imahiyerobo, an Advanced Practice Nurse at the Englewood Health Physician Network in New Jersey, led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity with i3 Health, New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia. A year later, Ms. Imahiyerobo sat down with Oncology Data Advisor to discuss additional advancements and updates in ITP management and patient care since recording.
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
At this weekend's American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.
At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the efficacy that HPN217 demonstrated in patients with relapsed/refractory multiple myeloma, including its tolerability and low risk of cytokine release syndrome (CRS).
In 2022, Dr. Maura Abbott, Associate Professor of Nursing at the Columbia University School of Nursing, served as faculty for i3 Health’s CME/NCPD approved activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia. Now, in this follow-up interview with Oncology Data Advisor, Dr. Abbott reinforces the importance of educating patients who are at risk for chemotherapy-induced neutropenia and shares some of the therapeutic developments in both prevention and management that are coming down the pipeline in the near future. Click here to view and claim credit for New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/new-cme/44-policies/503-i3health-com-cin
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia.Click here to view and claim credit for Therapy of B-Cell Acute Lymphoblastic Leukemia: an Evolving Landscape, an accredited CME/NCPD/CPE activity provided by i3 Health: https://i3health.com/odacon-all
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This podcast is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Listen now to earn free CME/NCPD!To claim credit, click here: i3health.com/oda-squamous-nsclc
In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.
At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.
Visit https://i3health.com/relapsed-refractory-multiple-myeloma to book a live or virtual meeting at your own institution and hear more expert perspectives from Dr. Kumar or other esteemed multiple myeloma faculty!Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.
Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about what to look forward to from this year's ASH Annual Meeting.
Dr. Jason Mouabbi of the MD Anderson Cancer Center sits down with Oncology Data Advisor to go over updates and highlights from the recent San Antonio Breast Cancer Symposium (SABCS).
In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them.
In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.
In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford Healthcare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.
This activity expires on MONDAY, DECEMBER 5!
In this podcast episode from i3 Health, expert faculty provide insight on new data and emerging strategies for patients with migraine headaches including prevention, treatment, and strategies for management related to adverse events and supportive care. Presented by Jessica Ailani, MD, Director, MedStar Georgetown Headache Center, MedStar Georgetown University Hospital, and Calli Cook, DNP, APRN, FNP-C, FAANP, Clinical Assistant Professor, Nell Hodgson Woodruff School of Nursing, Emory University. Listen now!
Click here to claim CME/NCPD/CPE credit: https://i3health.com/podcast-migraine
In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the May Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia (WM) session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.
This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Listen now!
Click here to claim CME/NCPD/CPE credit: https://i3health.com/sclc-treatment
Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.
In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.
Recently, Oncology Data Advisor hosted a live faculty panel discussion in advance of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, featuring the conference's four expert nurse speakers: Dr. Constance Visovsky, Abbey Kaler, Julia LaBarbera, and Janie Metsker. In their conversation, they gave a preview of the educational topics they'll be covering at ODACon on November 12, as well as highlighting their individual research interests and their work in the breast cancer community.
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer.
In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent’s Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them.
Understanding the various subtypes of breast cancer is critical, as treatment selection and potential outcomes depend heavily on subtype. In this latest Oncology Data Advisor interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, an Assistant Professor at the University of Texas MD Anderson Cancer Center, sheds light on lobular breast, an often-understudied subtype. Dr. Mouabbi shares his passion for raising awareness about lobular breast cancer and his goal of better understanding it at the genomic level to develop novel therapeutic options.
Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.
In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.
At the recent International Myeloma Society (IMS) Annual Meeting, Donna Catamero, NP, Associate Director of Myeloma Translational Research at Mount Sinai Hospital, presented her abstract regarding increasing clinical trial accrual of minority patients. In this interview, Ms. Catamero discusses her presentation, the disproportionate burden that minority patients experience, and why she believes the health care team should take action to create an equal space for everyone in the clinic.
At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.
At the recent International Myeloma Society (IMS) Annual Meeting, Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates and President of the Community Oncology Alliance, spoke about practical solutions for addressing disparities in multiple myeloma in the United States. In this follow-up interview with Oncology Data Advisor, Dr. Patel digs deep into the multifaceted factors that contribute to cancer disparities and shares his pioneering work that aims to ensure that every patient with cancer receives equitable access to care.
In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.
In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.
In this podcast from i3 Health gain expert insight and enhance your clinical knowledge with this case-based activity focusing on new and groundbreaking biomarkers used for diagnosis of graft-versus-host disease, factors for therapy selection, and clinical trial findings used to individualized treatment for patents, presented by leading faculty Shernan Holtan, MD, Associate Professor of Medicine, University of Minnesota, and Carrie Kitko, MD, Associate Professor of Pediatrics, Vanderbilt University Medical Center. Start the activity now!
Click here to claim CME/NCPD/CPE credit: https://i3health.com/oda-gvhd
Following the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Cherry Au, MD, of Rush University Medical Center, spoke with Oncology Data Advisor to discuss her abstract, Medical Student Clinical Cultural Awareness in Cancer Care of Sexual and Gender Minorities.
In this interview, Maura Abbott describes the current landscape of chemotherapy-induced neutropenia and the activity she co-led earlier this year.
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.
This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now!
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies’ results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.
Listen now for an expert-led discussion, presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health, as he provides the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more!
Click here to claim CME/NCPD credit: https://bit.ly/3oWpkZu
Presented by Dr. Shawn Kwatra, Director, John Hopkins Itch Center, Associate Professor of Dermatology, John Hopkins University School of Medicine and Dr. Linda Stein Gold, Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System, this expert led discussion will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease.
Click here to claim credit: https://i3health.com/atopic-dermatitis
In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Listen now to earn free CME/NCPD/CPE!
Click here to claim credit: https://bit.ly/3PGfd6Z
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Listen now!
Click here to claim CME/NCPD/CPE credit: https://bit.ly/3cy6PrK
This podcast, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Listen now to earn free CME/NCPD/CPE!
Claim credit here: https://bit.ly/3yI6GJo
This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Listen now to earn free CME/NPCD/CPE!
Click here to claim credit: https://bit.ly/3PdghPj
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Listen now to earn free CME | NCPD | CPE!
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Debra Lundquist, PhD, RN, of Massachusetts General Hospital and colleagues presented their poster that sought to bridge the gap between recent advances in individual therapy which led to improved outcomes and a better understanding of patient-reported hope, quality of life, symptom burden, and coping mechanisms in early phase clinical trial participants.
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!
Research has shown that Black American patients with multiple myeloma experience significant disparities in treatment patterns and outcomes compared with White patients. In this interview, Oncology Data Advisor editorial board member Dr. Rahul Banerjee speaks with Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas Medical School and a leading researcher in the field of multiple myeloma treatment disparities.
In this follow-up interview with Oncology Data Advisor, Reverend Sean expands on their thoughts and provides the valuable perspective of their personal experience as a transgender patient in the cancer care community
In this interview with Oncology Data Advisor, Ms. Rowe and Ms. Vigil Schattinger discuss their own experiences with medical aid in dying, explain their work to spread awareness and provide education to the community, and share additional advice for nurses on how to engage patients and families in meaningful conversations about this important issue.
In this interview with Oncology Data Advisor, Dr. Don S. Dizon, MD, continues the conversation he had at the recent 47th Annual Oncology Nursing Society (ONS) Congress, where he and three other professionals held a panel to spearhead the topic of improving quality of care for LGBTQIA+ individuals with cancer.
In honor of Oncology Nursing Month in May, Oncology Data Advisor is celebrating the stories of these essential members of the cancer care team. For this interview, editorial board member Maria Badillo, MSN, RN, OCN®, CCRP, speaks with Diane Barber, PhD, ANP-BC, AOCNP®, FAAN, Manager of Advanced Practice Providers at MD Anderson Cancer Center. Dr. Barber explains the importance of building a diverse nursing work force and shares ways to spread awareness about the opportunities that a career in nursing can offer.
i3 Health would like to extend a special invitation to join us for a live webinar in June focusing on T-cell lymphoma (TCL). This expert-led discussion, presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health, will offer valuable insights on diagnosis and evidence-based management of TCL.
Visit i3Health.com/tcl-webinar to reserve your seat today!
In honor of Oncology Nursing Month in May, Oncology Data Advisor is celebrating the stories of these essential members of the cancer care team. For this interview, editorial board member Maria Badillo, MSN, RN, OCN®, CCRP, speaks with Doyle Bosque, RN, Director of Nursing Research Programs at MD Anderson Cancer Center. Mr. Bosque explains the role that he plays in the oversight of clinical trials and shares the exciting opportunities that a career in research nursing can offer.
In honor of Oncology Nursing Month in May, editorial board member Maria Badillo speaks with Sherry Adkins about her groundbreaking research in the development of CAR T-cell therapies.
In honor of Melanoma Awareness Month, Dr. Shaheer Khan, Assistant Professor of Medicine at Columbia University Irving Medical Center, shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligible for immunotherapy, and offers advice for members of the multidisciplinary cancer care team who are treating patients with this disease.
Free CME and NCPD credit are available for this podcast. To claim credit, visit: i3Health.com/oda-ec.
Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine. Listen now!
For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individual patients with testicular cancer, with the goal of minimizing toxicity and achieving the best possible outcomes for treatment and surgery.
For patients with testicular cancer, planning is necessary to ensure that patients feel prepared regarding the implications of their disease in the years after they finish treatment. In this interview in honor of Testicular Cancer Awareness Month, Dr. Katie Murray, Assistant Professor at the University of Missouri Department of Surgery-Urology, shares advice for members of the cancer care team on how to counsel their patients on planning for life after testicular cancer.
In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Korde of Memorial Sloan Kettering Cancer Center about the potential of digital health tools to improve quality of life for patients with multiple myeloma.
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Listen now to earn free CME/NCPD!
This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery, strategies to address disparities in health care access for underserved populations, and the importance of taking a multidisciplinary approach to achieve the best possible outcomes for patients with testicular cancer.
This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be considered when selecting treatment options—including surgery, chemotherapy, radiation, or surveillance—for patients with testicular cancer, the future of recent advances such as cancer detection with microRNA, and the importance of taking a multidisciplinary approach to ensure the best possible outcomes for patients with this disease.
In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty about risk factors for the development of venous thromboembolism (VTE) in patients with multiple myeloma and the considerations for thromboprophylaxis during their treatment.
This expert-led episode of Oncology Data Advisor™, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. Listen now to earn free CME/NCPD!
In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma.
In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and editorial board member of Oncology Data Advisor, discusses the practice-changing significance of the approval of tebentafusp and delves further into future directions in the development of treatments for uveal melanoma.
In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma.
In this interview, Dr. Augusto Villanueva of Mount Sinai Hospital delves into the question of whether etiology should play a part in immune-based treatment selection for hepatocellular carcinoma (HCC), as well as the role of liquid biopsy for newly diagnosed patients.
In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS.
In honor of World Cancer Day, members of the Oncology Data Advisor (ODA) editorial board gathered to discuss the latest advances and future directions in oncology research. Dr. Thomas Abrams, an Assistant Professor of Medicine at Harvard Medical School shared recent progress in the field of gastrointestinal cancers; Dr. Ulka Vaishampayan, a Professor of Internal Medicine at the University of Michigan Rogel Cancer Center provided insights into current trends in genitourinary cancer research; and Beth Sandy, MSN, CRNP, an outpatient thoracic oncology nurse practitioner at the University of Pennsylvania Abramson Cancer Center, discussed recent and future treatment advances in the field of lung cancer.
Dr. Rahul Banerjee and Dr. Kelly Brassil discuss the design of an ongoing phase 2 trial investigating digital life coaching and its implications for improving the quality of life of patients undergoing ASCT for multiple myeloma.
In this interview, Dr. Thomas Abrams of Harvard Medical School discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This podcast is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Listen now to earn free CME/NCPD!
Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In this interview with Oncology Data Advisor, Dr. Matthew Davids of Harvard Medical School delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.
Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In this interview, Dr. Sumit Gupta explains the importance of recognizing health disparities among pediatric patients with ALL and the changes that can be implemented to address them.
Over recent years, numerous developments have occurred in the fields of breast cancer prevention, genetic testing, screening, and surgical procedures. In this interview, Dr. Brigid Killelea, Medical Director of Breast Surgery at Hartford HealthCare, explains strategies for incorporating these advances into the care of patients with breast cancer.
In this podcast episode from i3 Health, expert faculty provide insight on new data and emerging strategies for patients with migraine headaches including prevention, treatment, and strategies for management related to adverse events and supportive care. Presented by Jessica Ailani, MD, Director, MedStar Georgetown Headache Center, MedStar Georgetown University Hospital, and Calli Cook, DNP, APRN, FNP-C, FAANP, Clinical Assistant Professor, Nell Hodgson Woodruff School of Nursing, Emory University. Listen now!
Significant progress has been made in numerous facets of breast cancer care in recent years, including developments in treatment, imaging, pathology, radiation, and surgery. In this interview, Dr. Richard Zelkowitz, a Regional Medical Director of the Breast Program at Hartford HealthCare, highlights the advances that have been made and explains the importance of subspecialties in ensuring that patients with breast cancer receive the most individualized care possible.
For patients with breast cancer, the approach to treatment requires an individualized approach accounting for factors such as genetic risk, symptom management, and more recently, the challenges of the COVID-19 pandemic. In this interview, Dr. Valerie Brutus, a breast surgical oncologist at St. Vincent’s Medical Center of Hartford HealthCare, discusses strategies for successfully incorporating each of these factors into patients’ treatment.
In this recording of Oncology Data Advisor’s Live Breast Cancer Panel, three noted experts in breast cancer management partake in a conversation about recent advances in treatment, strategies and integrative medicine modalities to minimize toxicity, and techniques for enabling patients with breast cancer to thrive throughout their diagnosis and treatment.
How can members of the cancer care team enable breast cancer survivors to become breast cancer thrivers? Watch as Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation medical advisory council, explains how to provide optimal care and support for patients with breast cancer during their treatment and beyond.
Although the management of breast cancer has been impacted by the COVID-19 pandemic, the cancer care team has developed strategies to optimize screening and treatment experiences in spite of these challenges. In this podcast, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation medical advisory council, shares advice advice regarding protocols for undergoing mammograms during the pandemic, including the timing of COVID-19 vaccination.
This comprehensive activity podcast presented by faculty experts Aparna Parikh, MD, MS, Harvard Medical School, and Theresa Gillespie, PhD MA, RN, FAAN, Emory University School of Medicine, will focus on practice guidelines, emerging data on treatment combinations, and assessing strategies on improving the quality of patients life with BRAF V600–mutant metastatic CRC.
This podcast interview features Erin Prendergast, RN, CBCN®, an oncology nurse navigator and Senior Breast Clinical Coordinator in the Breast Cancer Program at UT Southwestern Simmons Comprehensive Cancer Center. Ms. Prendergast explains what she does in her role as an oncology nurse navigator and shares strategies that her team has implemented to ensure that patients with breast cancer receive optimal access to treatment and supportive care during the COVID-19 pandemic.
How can members of the cancer care team help their patients with breast cancer continue to thrive despite their diagnosis? Watch as Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation medical advisory council, shares how to enhance quality of life preservation and restoration for breast cancer patients and survivors.
For this podcast in honor of Breast Cancer Awareness Month, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation medical advisory council, discusses current standards and recent advances in breast cancer surgery, including lumpectomies, prophylactic mastectomies, and reconstructive procedures.
In this interview, in honor of Breast Cancer Awareness Month, Tricia Trammell, BA, CRA, FAHRA, R.T. (R)(M)(QM)(BS), CN-BI, Breast Center Manager at UT Southwestern Simmons Comprehensive Cancer Center, discusses the advancements in breast imaging in relation to screening for breast cancer.
In this interview in honor of Breast Cancer Awareness Month, Judy Herrick, RN, OCN®, ONN-CG, the Supervisor of Support Services at UT Southwestern Simmons Comprehensive Cancer Center, discusses the role of oncology nurse navigation and support services in ensuring that patients with breast cancer receive optimal care during their treatment. Ms. Herrick also discusses the importance of patient education and shares strategies for utilizing available resources to address all facets of breast cancer care.
In this interview, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and medical advisory council member of the National Breast Cancer Foundation, discusses the pathology of breast cancer, prognostic factors for disease outcomes, and the crucial role of breast pathologists in setting the stage for diagnosis and treatment.
In her latest Breast Cancer Awareness Month video, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation medical advisory council, discusses the importance of undergoing 3D mammography breast cancer screening, as well as the crucial role of breast imaging radiologists in this field.
In honor of prostate cancer awareness month, Dr. Ulka Vaishampayan, will be discussing issues surrounding prostate cancer.
In honor of Breast Cancer Awareness Month, Lillie Shockney RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and a member of the National Breast Cancer Foundation (NBCF) Medical Advisory Board, discusses the genetic factors that come into play in the development of breast cancer. In addition, she shares advice for which individuals should receive genetic testing and when, as well as strategies for counseling individuals who are undergoing genetic testing.
In honor of Breast Cancer Awareness Month, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and a member of the National Breast Cancer Foundation (NBCF) Medical Advisory Board discusses factors in the risk and prevention of breast cancer. Ms. Shockney shares advice for minimizing one's risk of developing breast cancer and explains the genetic factors that can come into play in the development of this disease.
On World Cancer Research Day, Dr. Thomas Abrams of Harvard Medical School discussed his career as a gastrointestinal cancer researcher and the progress that has been made in this field.
Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, including the safety and tolerability of emerging treatments, survivorship care, and much more. This podcast is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale New Haven Health. Listen now!
In this interview, Allison Imahiyerobo, APN, discusses strategies to optimize the treatment of immune thrombocytopenia (ITP).
In this podcast, Dr. Steven Horwitz from Memorial Sloan Kettering Cancer Center will be discussing recent advances in the treatment of T-cell lymphoma.
If you enjoyed this podcast and want to learn more on Updates on Therapeutic Advances in T-Cell Lymphoma, visit i3Health.com/t-cell-lymphoma-enduring
In this podcast, Dr. Sara Tolaney from Dana-Farber Cancer Institute will be discussing strategies to improve the management of metastatic breast cancer.
If you enjoyed this podcast and want to learn more on Optimizing Personalized Care Plans for Patients With Metastatic Breast Cancer, visit i3Health.com/metastatic-bc for free CME/NCPD.
In this podcast, Dr. Kelly Brassil, PhD, RN, from The University of Texas MD Anderson Cancer Center, will be discussing patient-reported symptom data and how it affects patient survival and quality of life.
If you enjoyed this podcast, and want to learn more on Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma with Dr. Kelly Brassil, visit https://i3health.com/ODA-HL for free CME.
To claim credit and obtain further information, including faculty disclosures, visit i3Health.com/ODA-cervical.
While the survival rate for localized cervical cancer is high, patients with metastatic disease face a poor prognosis with limited treatment options. This episode of Oncology Data Advisor will provide an update on immunotherapeutic strategies for recurrent and metastatic cervical cancer. It features perspectives from two noted experts in the field: Dr. Bradley Monk, Professor of Gynecologic Oncology at the University of Arizona College of Medicine; and Ms. Jennifer Filipi, nurse practitioner at Massachusetts General Hospital.
This activity is supported by an independent educational grant from Merck. Free CME and NCPD credit are available for this podcast.
To claim CME credit, visit https://i3health.com/oda-thyroid
While thyroid cancer is the most common endocrine cancer, prognosis and survival rates vary widely by subtype. This episode of Oncology Data Advisor will focus on advances in the management of differentiated and anaplastic thyroid cancers. It features perspectives from two noted experts in the field: Dr. Jochen Lorch, Director of the Thyroid Cancer Center at Dana-Farber Cancer Institute; and Ms. Carolyn Grande, Oncology Nurse Practitioner at Abramson Cancer Center.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com. Free CME and NCPD credit are available for this podcast. To claim credit and obtain further information, including faculty disclosures, visit i3Health.com/ODA-thyroid.
To claim credit visit https://i3health.com/ODA-HL
Hodgkin lymphoma is a rare malignancy that originates in the lymphatic system. Management challenges include the need to improve outcomes in advanced disease and optimize treatment tolerability in both younger and older patients. This episode of Oncology Data Advisor will focus on novel and emerging treatment strategies for advanced classical Hodgkin lymphoma. It features perspectives from two noted experts in the field: Dr. Kami Maddocks, Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital of The Ohio State University; and Dr. Kelly Brassil, Lead Care Manager at The University of Texas MD Anderson Cancer Center.
This activity is supported by an independent educational grant from Seagen. Free CME and NCPD credit are available for this podcast. To obtain further information and claim credit, visit i3Health.com/ODA-HL.
To claim CME credit, visit https://i3health.com/oda-itp
Immune thrombocytopenia is an acquired immune-mediated disorder with no known cause. Effective management is limited by lack of specific diagnostic criteria and other current gaps in knowledge. This episode of Oncology Data Advisor will focus on advances in the treatment of relapsed or refractory immune thrombocytopenia. It features perspectives from two noted experts in the field: Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse in Blood & Marrow Stem Cell Transplantation at the John Theurer Cancer Center, Hackensack Meridian Health.
Free CME and NCPD credit are available for this podcast. To claim credit, visit i3health.com/oda-EGFR-exon20-NSCLC.
EGFR exon 20 insertion mutations are associated with a worse prognosis than other types of EGFR-mutant non-small cell lung cancer, or NSCLC. This episode of Oncology Data Advisor will focus on new developments in the diagnosis and treatment of NSCLC with EGFR exon 20 insertion mutations. It features perspectives from two noted experts in the field: Dr. Helena Yu, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center; and Dr. Maria Arcila, Director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center.
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
To claim CME credit, visit https://i3health.com/oda-nsclc-kras
One of the two major subtypes of lung cancer, non-small cell lung cancer (NSCLC) is a challenging disease to treat, with most patients being diagnosed at a locally advanced or metastatic stage. Despite the use of tumor histology and relevant molecular biomarkers to determine treatment strategies, outcomes remain poor, with a 5-year survival rate of only 24%. In this episode of Oncology Data Advisor, Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, and Nathan Pennell, MD, PhD, Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute, discuss the role of acquired resistance mutations in first-line treatment selection, the potential for central nervous system (CNS) disease, and the efficacy and safety of novel treatment options for patients with ALK-positive advanced NSCLC.
To claim CME credit, visit https://i3health.com/burnout-in-oncology
Physician burnout and work-related stress are serious and prevalent issues in oncology, with nearly 45% of oncologists experiencing signs of burnout. Recently, this problem has been further exacerbated by the challenges brought about by the COVID-19 pandemic. In this episode of Oncology Data Advisor, Daniel McFarland, DO, an Instructor at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the varying factors that can contribute to physician burnout, advice for oncologists who are experiencing high levels of work-related stress, and institution-level changes that can be initiated in order to reduce burnout and foster wellness and engagement among oncologists.